Moderate to Severe

Juvenile Idiopathic Arthritis

Non-Infectious

Intermediate, Posterior and Panuveitis

Active

Psoriatic Arthritis

Moderate to Severe

Hidradenitis Suppurativa

Gastroenterology

Moderate to Severe

Crohn's Disease

Moderate to Severe

Pediatric Crohn's Disease

Moderate to Severe

Ulcerative Colitis

Moderate to Severe

Pediatric Ulcerative Colitis

Ophthalmology

Non-Infectious

Intermediate, Posterior and Panuveitis

Man in a blue swimsuit jumps into a lake

SKYRIZI VS COSENTYX® (secukinumab)2*

SUPERIOR RATES OF PASI 90 AT WEEK 52
IN AN OPEN-LABEL, ASSESSOR-BLINDED, HEAD-TO-HEAD STUDY

In an open-label, assessor-blinded study, IMMerge

SKYRIZI DEMONSTRATED SUPERIOR RATES OF PASI 90 AT WEEK 522

SOURCING:

In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab is not publicly available.3

The adverse events observed in this study were consistent with those observed in previously reported studies and as described in the full Prescribing Information for SKYRIZI and COSENTYX.* No new safety signals were observed through Week 52.1,2

*COSENTYX is a registered trademark of Novartis AG. See US Prescribing Information for further information.

87% OF SKYRIZI PATIENTS ACHIEVED PASI 90 AT WEEK 52 VS 57% OF COSENTYX® (secukinumab) PATIENTS (NRI)2

SKYRIZI® Demonstrated Superior rates of PASI 90 at Week 52 SKYRIZI® Demonstrated Superior rates of PASI 90 at Week 52 SKYRIZI® Demonstrated Superior rates of PASI 90 at Week 52

SKYRIZI 5 doses a year

and COSENTYX 16 doses a year

SOURCING:

In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab is not publicly available.3

The adverse events observed in this study were consistent with those observed in previously reported studies and as described in the full Prescribing Information for SKYRIZI and COSENTYX.* No new safety signals were observed through Week 52.1,2

STUDY DESIGN:

The head-to-head study was an open-label, assessor-blinded, 52-week study where patients were randomized 1:1 to receive either SKYRIZI 150 mg (two 75 mg injections) at Weeks 0, 4, and every 12 weeks until the last dose at Week 40; or COSENTYX* 300 mg (two 150 mg injections) at Weeks 0, 1, 2, 3, 4, and every 4 weeks until the last dose at Week 48.2

NRI=Non-responder imputation;
ITT=Intent-to-treat.

NRI=Non-responder imputation; ITT=Intent-to-treat.

*COSENTYX is a registered trademark of Novartis AG. See US Prescribing Information for further information.

In an open-label, assessor-blinded study, IMMerge

SKYRIZI DEMONSTRATED SUPERIOR RATES OF PASI 100 AND sPGA 0/1 AT WEEK 522

SOURCING:

In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab is not publicly available.3

The adverse events observed in this study were consistent with those observed in previously reported studies and as described in the full Prescribing Information for SKYRIZI and COSENTYX.* No new safety signals were observed through Week 52.1,2

*COSENTYX is a registered trademark of Novartis AG. See US Prescribing Information for further information.

SECONDARY ENDPOINT DATA2

SKYRIZI® Demonstrated Superior rates of PASI 100 and sPGA 0/1 at Week 52 SKYRIZI® Demonstrated Superior rates of PASI 100 and sPGA 0/1 at Week 52 SKYRIZI® Demonstrated Superior rates of PASI 100 and sPGA 0/1 at Week 52

SOURCING:

In this study, 46 patients outside of the US received non–US-licensed secukinumab. Data regarding comparability between US and non-US secukinumab is not publicly available.3

The adverse events observed in this study were consistent with those observed in previously reported studies and as described in the full Prescribing Information for SKYRIZI and COSENTYX.* No new safety signals were observed through Week 52.1,2

STUDY DESIGN:

The head-to-head study was an open-label, assessor-blinded, 52-week study where patients were randomized 1:1 to receive either SKYRIZI 150 mg (two 75 mg injections) at Weeks 0, 4, and every 12 weeks until the last dose at Week 40; or COSENTYX* 300 mg (two 150 mg injections) at Weeks 0, 1, 2, 3, 4, and every 4 weeks until the last dose at Week 48.2

NRI=Non-responder imputation;
ITT=Intent-to-treat.

NRI=Non-responder imputation; ITT=Intent-to-treat.

*COSENTYX is a registered trademark of Novartis AG. See US Prescribing Information for further information.


Well-Studied Safety Profile

across 4 pivotal trials1

Checklist Icon

Only 4 doses per year

3-month dosing after 2 initiation doses at
Weeks 0 and 4 (150 mg/dose)1

Calendar Icon
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127

REFERENCES

  1. SKYRIZI [package insert]. North Chicago, IL: AbbVie Inc.
  2. Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50-59. doi:10.1111/bjd.19341
  3. Data on file, ABVRRTI70649.
  4. Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650-661.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated. Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Infection SKYRIZI® may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves
IMPORTANT SAFETY INFORMATION AND INDICATION FOR SKYRIZI® (risankizumab-rzaa)1
Indication

SKYRIZI is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Important Safety Information

Infection

SKYRIZI® (risankizumab-rzaa) may increase the risk of infection. Do not initiate treatment with SKYRIZI in patients with a clinically important active infection until it resolves or is adequately treated.

In patients with a chronic infection or a history of recurrent infection, consider the risks and benefits prior to prescribing SKYRIZI. Instruct patients to seek medical advice if signs or symptoms of clinically important infection occur. If a patient develops such an infection or is not responding to standard therapy, closely monitor and discontinue SKYRIZI until the infection resolves.

Tuberculosis (TB)

Prior to initiating treatment with SKYRIZI, evaluate for TB infection and consider treatment in patients with latent or active TB for whom an adequate course of treatment cannot be confirmed. Monitor patients for signs and symptoms of active TB during and after SKYRIZI treatment. Do not administer SKYRIZI to patients with active TB.

Administration of Vaccines

Avoid use of live vaccines in patients treated with SKYRIZI. Medications that interact with the immune system may increase the risk of infection following administration of live vaccines. Prior to initiating SKYRIZI, complete all age appropriate vaccinations according to current immunization guidelines.

Adverse Reactions

Most common (≥1%) adverse reactions associated with SKYRIZI include upper respiratory infections, headache, fatigue, injection site reactions, and tinea infections.

SKYRIZI is available in a 150 mg/mL prefilled syringe and pen.

Please see Full Prescribing Information.

US-SKZD-210127